Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Jul 2016 |
| Genmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL | 23 Jun 2016 |
| Articles of Association for Genmab A/S | 14 Jun 2016 |
| Grant of Warrants to Genmab Employees | 9 Jun 2016 |
| Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis | 2 Jun 2016 |
| Genmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference | 31 May 2016 |